Crossmark

Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis

Published Online: 2024-10-28

Authors

Liu, Chang

Wu, Yao

Wang, Fangxu

Sun, Shuang

Wei, Jiayin

Tao, Libo
License Information

Text and Data Mining valid from 2024-10-28

Version of Record valid from 2024-10-28
More Information

Article History

Received: 18 March 2024

Accepted: 22 September 2024

First Online: 28 October 2024

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current